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Fibroblast growth factor 15 (Fgf15), a hormone made by the terminal ileum in response to bile acids, represses hepatic bile
acid biosynthesis. Choi and coworkers (2006) demonstrate that Fgf15 is also required for gallbladder filling.Bile acids (BAs) are the major constitu-
ents of bile. Bile is secreted from the he-
patocytes into the bile canaliculi and ulti-
mately ends up in the hepatic duct. About
one-half of the secreted bile is diverted to
the cystic duct and stored in the gallblad-
der. After eating a meal, food enters the
duodenum leading to the production of
cholecystokinin (CCK). CCK is a peptide
hormone, which stimulates contraction
of the gallbladder and relaxation of the
sphincter of Oddi promoting bile flow
via the common bile duct into the duo-
denum (Figure 1). BAs are amphipathic
molecules essential for solubilization of
dietary lipids and fat-soluble vitamins,
which subsequently promotes absorp-
tion of these molecules in the digestive
tract. BAs are efficiently reabsorbed by
passive diffusion and active transport
from the terminal ileum and transported
back to the liver via the portal vein com-
pleting their enterohepatic circulation. In
addition to this classic role in dietary lipid
absorption, it is now clear that BAs are
also signaling molecules that regulate
their own homeostasis by activating the
nuclear receptor farnesoid X receptor
(FXR) (reviewed in Houten and Auwerx
[2004]). Initial studies showed that he-
patic FXR activation by elevated BA
levels inhibits BA biosynthesis. FXR
induces the expression of short hetero-
dimer partner (SHP), which in turn
potently inhibits the expression of cho-
lesterol 7a-hydroxylase (CYP7A1), the
rate-limiting enzyme in BA biosynthesis
(Goodwin et al., 2000; Lu et al., 2000). It
is now clear that FXR in the ileum is pre-
dominantly responsible for this feedback
inhibition (Inagaki et al., 2005). Via FXR,
BAs stimulate the expression of mouse
Fgf15 (Inagaki et al., 2005) and its human
ortholog FGF19 (Holt et al., 2003). All cur-
rent available evidence indicates that
Fgf15 and FGF19 have similar functions
in BA homeostasis, although there are
no human studies to substantiate this.
For reasons of clarity, I will use the
name Fgf15 for both Fgf15 and FGF19
in this preview. Fgf15 is highly expressed
in ileum and only at low levels in other en-
terohepatic organs. FGFs mediate theirCELL METABOLISM : DECEMBER 2006biological actions by binding to trans-
membrane FGF receptors (FGFR), which
are tyrosine kinase receptors encoded
by four independent genes (FGFR1-4).
Fgf15 binds to hepatic Fgfr4, leading to
repression of CYP7A1 expression via a
signaling mechanism that involves both
SHP and c-Jun N-terminal kinase (JNK,
a stress signaling kinase; Figure 1) (Holt
et al., 2003; Inagaki et al., 2005).
Now Choi and coworkers demonstrate
that Fgf15 is also required for gallbladder
filling (Choi et al., 2006). They show that
gallbladders are almost empty in mice
lacking Fgf15. Administration of recombi-
nant Fgf15 resulted in an increase in the
volume of the gallbladder in Fgf15 knock-
out mice but also in wild-types. Impor-
tantly, bile flow was not dependent on
Fgf15, showing that the effect on gall-
bladder volume is caused by decreased
emptying in the duodenum rather then in-
creased bile production. Experiments in
Fgfr4 knockout mice indicate that in con-
trast to liver, the effects of Fgf15 on the
gallbladder are not exclusively mediated
by Fgfr4. Expression analysis of all four
FGFRsshowed that gallbladder, bileduct,
and sphincter of Oddi express relative
high levels ofFgfr3, suggesting that Fgf15
mediates its effects via this receptor.In their study, Choi and coworkers
also analyzed CCK levels in the fasted
and postprandial state in wild-type and
Fgf15 knockout mice. As expected,
CCK increased after a meal, but this in-
crease was significantly lower in the
Fgf15 knockouts. Although interesting
by itself, this indicates that changes in
CCK levels are not the cause for the
empty gallbladders in Fgf15 knockouts.
Intravenous administration of CCK re-
duced gallbladder volume, but coadmin-
istration of an excess of Fgf15 blocked
the effect of CCK, indicating that both
hormones have an antagonizing action
on the gallbladder.
Cyclic nucleotides such as cyclic AMP
(cAMP) relax the gastrointestinal smooth
muscle and are mediators in gallbladder
filling (Morales et al., 2004). Consistent
with this, Choi et al. (2006) showed that
CCK decreases gallbladder cAMP, which
is reversed by Fgf15. Both forskolin, an
activator of adenylate cyclase, and Fgf15
increased gallbladder volume and cAMP
levels, which further indicates that Fgf15
induces smooth muscle relaxation via
cAMP. Much of the regulation of gall-
bladder motility is neuronal. In order
to demonstrate that Fgf15 has direct
effects on the gallbladder, the authorsFigure 1. Schematic representation of the actions of Fgf15 on liver and gallbladder
Bile acids (BAs) are synthesized in the liver from cholesterol and are secreted into the hepatic duct. They can
either be stored in the gallbladder or flow into the duodenum. In the terminal ileum, BAs activate FXR, leading
to the production of Fgf15. In the liver, Fgf15 inhibits transcription of CYP7A1, the rate-limiting enzyme in BA
biosynthesis. Fgf15 also relaxes the smooth muscle of the gallbladder. The latter is action is required for gall-
bladder filling.423
P R E V I E W Sperformed ex vivo tensiometry with iso-
lated gallbladders. Tension in the gallblad-
ders increased by the addition of CCK.
Both Fgf15 and forskolin caused relaxa-
tion of this CCK-induced gallbladder con-
traction. Combined, these data indicate
that Fgf15 directly stimulates gallbladder
filling via cAMP-dependent relaxation of
the smooth muscle (Figure 1).
Although smooth muscle tension is im-
portant for gallbladder filling, it is essen-
tial that the pressure in the common
duct is greater than in the cystic duct
(Hofmann, 1999b). This can be achieved
by contraction of the sphincter of Oddi. It
is therefore essential to investigate a po-
tential role of Fgf15 on the tone in the
sphincter of Oddi. Storage of bile in the
gallbladder is of functional importance.
During storage, the bile is concentrated
by water removal in order for BAs to
reach concentrations in the intestinal lu-
men high enough to solubilize dietary
lipids (Hofmann, 1999a). It will be in-
teresting to investigate whether Fgf15-
deficient mice have a deficiency in con-
centrating bile and as a result decreased
absorption of dietary lipids. Fgf15 is an424FXR target, and it is therefore surprising
that gallbladder filling is not reported to
be deficient in FXR knockout animals
(Moschetta et al., 2004). The generation
of intestinal specific FXR knockout mice
is expected to shed light on the emerging
role of ileal FXR on gallbladder filling and
CYP7A1 downregulation.
Concluding, Fgf15 ensures that BAs
can return to their home. With the current
and future work on Fgf15, biology is
homing in on BA physiology.
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